Research

At the University of Illinois, Chicago, Dr. Chan’s Current Research Projects Include: 

  • HIV – Being the largest overall healthcare provider in the United States, the Veterans Affairs (VA) health care system is also the largest provider of HIV care in the US.  The VA cared for about 17,000 patients with HIV in fiscal year 1999, providing approximately one million outpatient visits and 170,000 days of hospital care.  HIV testing continues to be a high priority for the VA, especially given that patients with certain HIV risk factors, (e.g., intravenous drug abuse, homelessness) are overrepresented among VA patients.  However, many at-risk VA patients are not tested for HIV.  Previous studies showed that only 30-50% of VA patients with documented risk factors have undergone HIV testing.  As a consequence, many HIV-positive patients are diagnosed later in the disease course than is optimal.  The objectives of my research are to develop methods using system sciences as an innovative approach to assess the organizational cost in the implementation of an expanded HIV testing program, and the long-term goals to extend the new knowledge into more efficient and effective implementation strategies in comparative studies of the VA healthcare system (with electronic medical records) and other non-VA systems.  As the new era of the implementation of universal health care reform, there is much to learn from a VA-healthcare system and to adopt new and fresh of delivery of health care and preventive care for the population in general.
  •  HCV – Research has shown that by the year 2020 there will be an increasing number of patients with hepatitis C (HCV) worldwide, and currently, the Veterans Affairs Healthcare system, being the largest medical care provider to HCV patients, is estimated to identify and treat more patients in the next decade.  Computer models can simulate the system effects of introducing new medications by incorporating estimates of drug prices, rates of treatment with the new drugs, possible increases in patients treated, and other key parameters. Patient and provider preferences about how to balance short- and long-term benefits and risks of therapies are not known, and will be important to the cost impacts of new drug combinations to the VA. The objectives of my research are to evaluate the patient and provider’s preferences of new HCV drug regimen, and then, using quantitative preferences, to model how the introduction of powerful protease-based HCV therapies will influence treatment patterns. The long-term outcomes of my research  are 1) analyses of patients’ and providers’ preferences for new therapeutic approaches, and 2) cost-benefit analyses of using new HCV drug regimens from a patient and providers’ perspectives. The new knowledge will be critical to help inform VA decision makers at different levels in tailoring programmatic responses aimed at improved delivery of care and patient outcomes with HCV.
  • Mental Health – Even though medication can prolong patients with HIV, hepatitis and chronic diseases, patients are often experience stress and have difficult managing stress which can decrease immune responses and affect quality of life.  Collaborating with UC San Diego, we are evaluating the cost-effectiveness analysis of new cognitive behavior therapy, meditation, and stress reduction programs compared to traditional pharmacological management.  These stress reduction programs have success in stress reduction in patients and medical providers.
  •  Genetic Testing- Population-based genetic testing in infants for metabolic disorder and genetic diseases before the manifestation of symptoms can improve survival and save lives.  Using mathematical models to evaluate the cost and benefits of implementing a population-based newborn screening program are important to guide policy recommendation and allocation of resources.  Since the publication of the methods (Chan and Puck, 2005), the states of Wisconsin and Massachusetts adopted the assay to screen for babies for severe combined immunodeficiency (SCID).  In our research group, we plan to develop models to balance the benefits and harms of expanding genetic screening and the impact of new screening recommendations on the delivery of child health services.